{"id":392504,"date":"2020-12-03T07:33:27","date_gmt":"2020-12-03T12:33:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392504"},"modified":"2020-12-03T07:33:27","modified_gmt":"2020-12-03T12:33:27","slug":"cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/","title":{"rendered":"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Dec.  03, 2020  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31<sup>st<\/sup> International Symposium on ALS\/MND taking place online from December 9 \u2013 December 11, 2020.<\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong><br \/>\n        <strong>A Phase 3, Multi-Center,<\/strong><br \/>\n        <strong>Double-Blind, Randomized, Placebo<\/strong><br \/>\n        <strong>Controlled Trial to Evaluate the<\/strong><br \/>\n        <strong>Efficacy and Safety of <\/strong><br \/>\n        <strong><br \/>\n          <em>Reldesemtiv<\/em><br \/>\n        <\/strong><br \/>\n        <strong> in<\/strong><br \/>\n        <strong>Patients with Amyotrophic Lateral<\/strong><br \/>\n        <strong>Sclerosis (ALS): COURAGE-ALS Trial<\/strong><br \/>\n        <strong>Design<\/strong><br \/>\n        <br \/>Session: Live Poster Session A<br \/>Date: December 9, 2020<br \/>Theme: 09 \u2013 Clinical Trials and Trial Design<br \/>Presentation Time: 5:10 \u2013 5:50 PM GMT<br \/>Poster Number: CLT-04<br \/>Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at\u00a0Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the\u00a0University of Arizona,\u00a0Phoenix<\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong><br \/>\n        <strong>Impact of Patient<\/strong><br \/>\n        <strong>Characteristics on Effect Size in<\/strong><br \/>\n        <strong>FORTITUDE-ALS<\/strong><br \/>\n        <br \/>Session: Live Poster Session B<br \/>Date: December 10, 2020<br \/>Theme: 09 \u2013 Clinical Trials and Trial Design<br \/>Presentation Time: 5:10 \u2013 5:50 PM GMT<br \/>Poster Number: CLT-17<br \/>Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at\u00a0Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the\u00a0University of Arizona,\u00a0Phoenix<\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong><br \/>\n        <strong>People Living with ALS and Their Caregivers\u2019 Input <\/strong><br \/>\n        <strong>into Drug Development in Europe<\/strong><br \/>\n        <br \/>Session: Live Poster Session C<br \/>Theme: 13 \u2013 Clinical Management, Support and Information<br \/>Date: December 11, 2020<br \/>Presentation Time: 12:05 \u2013 12:50 PM GMT<br \/>Poster Number: CMS-33<br \/>Poster Presenter: Miriam Galvin, Ph.D., Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin<\/p>\n<p align=\"justify\">\n        <strong>About Cytokinetics<\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and\/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for <em>omecamtiv<\/em><em>mecarbil<\/em>, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of <em>omecamtiv<\/em><em>mecarbil<\/em>. Cytokinetics is also developing CK-274, a next- generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing <em>reldesemtiv<\/em>, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of <em>reldesemtiv<\/em> to Phase 3 pending ongoing regulatory interactions. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.<\/p>\n<p align=\"justify\">For additional information about\u00a0Cytokinetics, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2My0u_gEc3xpH_7bx27M86t5v3vn0PtiJ98u5cqDTZtp5Og6BJGbx5oZF12TOK0Z0TI83lUvGLhPa--X2aYeDxTN35_DuGmyIoQlH_bVCKM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V2exZKGpAtcuSJdNYEO6AB6maSzfMCpfbvXNPvHQdliZEkHDDY_e5LXvDBes3nX4rzdQ2EUqptcXRuVrM34WqA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vIxivc7R5WDyKX_l7jfD5QS7chkxxSyYwOWJvSGhu38CXp73jOKY8WrdcV1c3jMKOPlriV9r1zKmju3zzxogABxg1cpBl-LrrnvoLz2vLl4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M3Zles0nzI2LK6FOcchOlekyinjX8Tif6MSUSiqWDIFW9-Y5DgxZzRtMx2nps-mtcTioVk_U1lnAz5GQe_hn0WCjCAAqdf8LsBYC03occN0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gsNMrx85tJqT5LWvM6z2BlDBT6B7yjMtwiymEiZAmJXMFhg5xinkEgmrpoqykRUYQ2Nh6RhZQrmWd9dECOxt9m4CChoCsnf4Vvk2WfNFa-LWMXWBHs4bjPcSDrmQAgh_\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act&#8217;s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential benefits of <em>reldesemtiv<\/em>, including its ability to represent an additive and complementary approach to increase muscle function; Cytokinetics\u2019 and its partners\u2019 research and development activities; the timing of enrollment of patients in Cytokinetics\u2019 and its partners\u2019 clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics\u2019 drug candidates. Such statements are based on management&#8217;s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics\u2019 drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics\u2019 drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics\u2019 or its partners\u2019 ability to conduct clinical trials; and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas\u2019 decisions with respect to the design, initiation, conduct, timing and continuation of development activities for <em>reldesemtiv<\/em>; standards of care may change, rendering Cytokinetics\u2019 drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics\u2019 drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics\u2019 collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics\u2019 business, investors should consult Cytokinetics\u2019 filings with the Securities and Exchange Commission.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Cytokinetics<br \/>Diane Weiser<br \/>Senior Vice President, Corporate Communications, Investor Relations<br \/>(415) 290-7757<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b9156ed0-75e6-45e6-b281-be2f71195525\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS\/MND taking place online from December 9 \u2013 December 11, 2020. Title: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS): COURAGE-ALS Trial Design Session: Live Poster Session ADate: December 9, 2020Theme: 09 \u2013 Clinical Trials and Trial DesignPresentation Time: 5:10 \u2013 5:50 PM GMTPoster Number: CLT-04Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at\u00a0Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the\u00a0University of Arizona,\u00a0Phoenix Title: Impact of Patient &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392504","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS\/MND taking place online from December 9 \u2013 December 11, 2020. Title: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS): COURAGE-ALS Trial Design Session: Live Poster Session ADate: December 9, 2020Theme: 09 \u2013 Clinical Trials and Trial DesignPresentation Time: 5:10 \u2013 5:50 PM GMTPoster Number: CLT-04Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at\u00a0Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the\u00a0University of Arizona,\u00a0Phoenix Title: Impact of Patient &hellip; Continue reading &quot;Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T12:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Announces Three Presentations at the International Symposium on ALS\\\/MND\",\"datePublished\":\"2020-12-03T12:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/\"},\"wordCount\":814,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/\",\"name\":\"Cytokinetics Announces Three Presentations at the International Symposium on ALS\\\/MND - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=\",\"datePublished\":\"2020-12-03T12:33:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Announces Three Presentations at the International Symposium on ALS\\\/MND\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS\/MND taking place online from December 9 \u2013 December 11, 2020. Title: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS): COURAGE-ALS Trial Design Session: Live Poster Session ADate: December 9, 2020Theme: 09 \u2013 Clinical Trials and Trial DesignPresentation Time: 5:10 \u2013 5:50 PM GMTPoster Number: CLT-04Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at\u00a0Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the\u00a0University of Arizona,\u00a0Phoenix Title: Impact of Patient &hellip; Continue reading \"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T12:33:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND","datePublished":"2020-12-03T12:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/"},"wordCount":814,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/","name":"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=","datePublished":"2020-12-03T12:33:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA2MSMzODU0NDc2IzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Announces Three Presentations at the International Symposium on ALS\/MND"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392504"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392504\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}